Catalyst Pharmaceutical Partners, Inc. Announces FDA Designation Of CPP-115 As Fast Track Development Program

Catalyst Pharmaceutical Partners, Inc. announced that its investigational drug, CPP-115, a GABA aminotransferase inhibitor, has been designated as a Fast Track development program by the FDA for the treatment of cocaine dependency. CPP-115 is a GABA aminotransferase inhibitor and vigabatrin analogue that is more potent than vigabatrin and has reduced side effects from those associated with vigabatrin in preclinical studies. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and other selected CNS diseases, and recently initiated a Phase I safety study in 48 healthy subjects. CPP-115 has also been granted orphan-drug designation by the FDA for the treatment of infantile spasms.